Claviceps Purpurea Sclerotium

Dosage for Claviceps Purpurea Sclerotium varies significantly based on its application. Because this substance is primarily used as an allergenic extract, there is no 'standard' oral dose for general health.

Allergenic Testing (Diagnostic)

• Skin Prick Test: Usually, one drop of a 1:10 or 1:20 w/v (weight/volume) extract is applied to the skin.
• Intradermal Test: If the skin prick test is negative, a much more dilute solution (e.g., 0.02 mL of a 1:1000 or 1:500 dilution) may be injected into the dermal layer of the skin.

Therapeutic Derivatives

If a patient is prescribed a purified derivative (like ergotamine tartrate), the typical adult dose for an acute migraine attack is 2 mg initially, followed by 1 mg every 30 minutes if needed, not to exceed 6 mg per attack or 10 mg per week.

Claviceps Purpurea Sclerotium extracts are generally not recommended for use in children unless specifically required for allergy mapping by a pediatric allergist.

• Safety Note: The safety and efficacy of ergot-based products in pediatric populations have not been established. Most clinicians avoid these agents in children due to the high risk of severe vasoconstriction and potential growth plate interference.

Renal Impairment

Patients with impaired kidney function may experience decreased clearance of ergot metabolites. While no specific dosing scale exists for the allergenic extract, systemic ergot derivatives are generally contraindicated in severe renal failure (GFR < 30 mL/min) due to the risk of increased systemic toxicity.

Hepatic Impairment

Since the liver (CYP3A4) is the primary metabolic pathway, patients with hepatic cirrhosis or significant liver dysfunction should avoid Claviceps Purpurea Sclerotium. Reduced metabolic capacity significantly increases the risk of ergotism (toxic ergot poisoning).

Elderly Patients

Geriatric patients are at a higher risk for peripheral vascular disease and cardiovascular complications. Dosing of any ergot-related product must be approached with extreme caution, starting at the lowest possible diagnostic concentration.

As a diagnostic extract, Claviceps Purpurea Sclerotium is administered exclusively by a healthcare professional in a clinical setting equipped to handle anaphylaxis.

1. 1Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
2. 2Application: A drop of the extract is placed on the skin, and a sterile lancet is used to prick the surface.
3. 3Observation: The site is monitored for 15 to 20 minutes for a reaction.
4. 4Storage: Vials of the extract must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze.

In the context of allergy testing, a missed appointment simply requires rescheduling. For those taking ergot derivatives for migraines, a missed dose should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. Never double the dose to catch up.

An overdose of Claviceps Purpurea Sclerotium is a medical emergency known as Acute Ergotism.

• Symptoms: Severe numbness and tingling in the extremities (fingers and toes), cold or pale skin, muscle pain, rapid or weak pulse, confusion, seizures, and intense vomiting.
• Emergency Measures: If ingestion is suspected, call 911 or your local poison control center immediately. Treatment involves supportive care, vasodilators (like nitroprusside), and anticoagulants to prevent gangrene.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or use ergot-based products without direct medical guidance.

When used as an allergenic extract for skin testing, the most common side effects are localized to the site of administration:

• Pruritus (Itching): Intense itching at the test site is expected if the patient is allergic.
• Wheal and Flare: A raised, red bump (similar to a mosquito bite) that typically resolves within 2 to 4 hours.
• Local Erythema: Redness of the skin surrounding the application area.

If systemic ergot alkaloids are present, patients frequently report:

• Nausea and Vomiting: Often severe, caused by direct stimulation of the chemoreceptor trigger zone in the brain.
• Dizziness: A feeling of lightheadedness or vertigo.

• Abdominal Pain: Cramping or gastric distress.
• Paresthesia: Numbness or a 'pins and needles' sensation in the hands and feet.
• Headache: Paradoxically, while used to treat migraines, 'rebound' headaches can occur with frequent use.
• Localized Edema: Swelling that extends beyond the immediate test site.

• Ergotism (St. Anthony's Fire): A rare but devastating condition where severe vasoconstriction leads to gangrene of the fingers and toes.
• Hallucinations: Mental status changes, including vivid visual disturbances, due to the structural similarity of ergot alkaloids to LSD.
• Cardiac Ischemia: Chest pain or myocardial infarction (heart attack) caused by constriction of the coronary arteries.
• Uterine Hypertonus: Excessive contraction of the uterus, which can be dangerous in pregnant women.

> Warning: Stop using any ergot-related product and call your doctor immediately if you experience any of these symptoms.

1. 1Peripheral Ischemia: Signs include cold, pale, or blue-tinted fingers or toes, loss of sensation in the extremities, or a lack of pulse in the arms or legs.
2. 2Anaphylaxis: A life-threatening allergic reaction characterized by swelling of the throat, difficulty breathing, a rapid drop in blood pressure, and hives.
3. 3Cerebrovascular Accident (Stroke): Sudden weakness on one side of the body, slurred speech, or facial drooping.
4. 4Severe Hypertension: A sudden, dangerous rise in blood pressure that can cause a 'thunderclap' headache or vision changes.
5. 5Gangrene: Blackening of the skin on the extremities, indicating tissue death from lack of blood flow.

Prolonged exposure to Claviceps Purpurea Sclerotium alkaloids can lead to Fibrotic Complications. This includes the thickening of heart valves (valvular heart disease), pleural fibrosis (scarring of the lung lining), and retroperitoneal fibrosis (which can block the tubes that carry urine from the kidneys to the bladder). These effects are often irreversible and require surgical intervention.

While the raw sclerotium extract itself may not carry a specific black box warning in all jurisdictions, its primary active constituents (such as ergotamine) carry a Serious Drug Interaction Warning.

FDA BLACK BOX SUMMARY: Co-administration of ergot alkaloids with potent CYP3A4 inhibitors (including protease inhibitors and macrolide antibiotics) is contraindicated. This combination leads to elevated serum levels of the drug, resulting in life-threatening peripheral ischemia and gangrene.

Report any unusual symptoms, especially changes in skin color or temperature in your extremities, to your healthcare provider immediately.

Claviceps Purpurea Sclerotium is a highly bioactive substance that must be handled with extreme caution. It is not suitable for self-administration. The primary risk associated with this substance is its potent vasoconstrictive property, which can cut off blood flow to vital organs and extremities. All patients undergoing testing or treatment must be screened for pre-existing vascular and cardiac conditions.

No FDA black box warnings exist specifically for the Non-Standardized Allergenic Extract form of Claviceps Purpurea Sclerotium. However, the FDA mandates a Black Box Warning for all pharmaceutical products derived from its alkaloids (e.g., ergotamine) regarding the risk of severe ischemia when combined with CYP3A4 inhibitors. Clinicians should treat the raw extract with the same level of caution as these purified derivatives.

• Vascular Disease: This substance is strictly contraindicated in patients with peripheral vascular disease (PVD), Raynaud's syndrome, or Buerger's disease, as it can trigger immediate and irreversible tissue necrosis.
• Cardiovascular Risk: Patients with coronary artery disease or a history of angina should avoid this substance, as it can cause coronary vasospasm.
• Hypertension: Claviceps Purpurea Sclerotium can cause significant increases in blood pressure. It should be used with caution in patients with uncontrolled hypertension.
• Anaphylaxis Risk: As an allergenic extract, there is a constant risk of systemic allergic reactions. Testing should only be performed in facilities where epinephrine and airway management tools are available.

For patients exposed to significant amounts of ergot-related compounds, the following monitoring is required:

1. 1Circulatory Checks: Regular assessment of pulses, skin temperature, and color in the hands and feet.
2. 2Blood Pressure: Frequent monitoring during the diagnostic or therapeutic window.
3. 3Renal and Hepatic Function: Baseline and periodic BUN, Creatinine, and LFTs (Liver Function Tests) to ensure the body can clear the alkaloids.
4. 4Echocardiography: If long-term use of derivatives is required, periodic heart ultrasounds are necessary to check for valvular fibrosis.

This substance may cause dizziness, confusion, or visual disturbances. Patients should not drive or operate heavy machinery until they are certain the effects of the extract or its derivatives have completely worn off.

Alcohol should be avoided. Alcohol can exacerbate the vasodilatory or vasoconstrictive imbalances caused by ergot alkaloids and may increase the severity of nausea and headaches.

Abrupt discontinuation of ergot-based medications after long-term use can result in 'withdrawal' symptoms, primarily severe rebound headaches and tachycardia (rapid heart rate). A tapering schedule under medical supervision is often required.

> Important: Discuss all your medical conditions, especially any history of heart or circulatory problems, with your healthcare provider before starting Claviceps Purpurea Sclerotium.

• Potent CYP3A4 Inhibitors: This includes medications like ritonavir, clarithromycin, erythromycin, and itraconazole. These drugs block the metabolism of ergot alkaloids, leading to toxic levels in the blood and a high risk of gangrene and stroke.
• Vasoconstrictors: Drugs like epinephrine or other ergot derivatives should not be used concurrently, as the additive effects can lead to extreme hypertension and ischemia.

• Beta-Blockers: Combining beta-blockers (like propranolol) with Claviceps Purpurea Sclerotium can lead to excessive vasoconstriction because the beta-blocking action leaves the alpha-adrenergic vasoconstrictive action unopposed.
• Triptans: Migraine medications like sumatriptan should not be used within 24 hours of ergot-related products, as they both cause blood vessel narrowing and can lead to prolonged vasospasm.
• SSRIs and SNRIs: There is a risk of Serotonin Syndrome when used with ergot alkaloids, as many of these compounds have serotonergic activity.

• Nicotine: Smoking or using nicotine products causes further vasoconstriction and increases the risk of peripheral ischemia when using ergot-related substances.
• Nitrates: While ergot derivatives are sometimes classified as nitrate vasodilators in specific contexts, they can actually interfere with the efficacy of nitroglycerin used for chest pain.

• Grapefruit Juice: Grapefruit is a known inhibitor of the CYP3A4 enzyme. Consuming grapefruit juice while taking ergot derivatives can dangerously increase the concentration of the drug in your system.
• Caffeine: Caffeine increases the absorption rate of ergotamine. While sometimes used therapeutically (e.g., Cafergot), it can also increase the risk of side effects like jitteriness and tachycardia.

• St. John's Wort: This herb induces CYP3A4, which may lead to reduced efficacy of ergot derivatives by speeding up their clearance from the body.
• Ginkgo Biloba: May increase the risk of bleeding or interfere with the vascular effects of the sclerotium.

Claviceps Purpurea Sclerotium may interfere with certain diagnostic tests:

• Urine Catecholamine Tests: May produce false-positive results due to the adrenergic nature of the alkaloids.
• Prolactin Levels: Ergot derivatives like bromocriptine significantly lower prolactin levels, which may interfere with tests for pituitary function.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as the risk of ergotism is highly dependent on drug interactions.

Claviceps Purpurea Sclerotium must NEVER be used in the following conditions:

1. 1Pregnancy: Ergot alkaloids are potent oxytocics. They cause powerful uterine contractions that can lead to miscarriage, fetal distress, or maternal uterine rupture. They also cause placental vasoconstriction, starving the fetus of oxygen.
2. 2Peripheral Vascular Disease (PVD): Including Raynaud's phenomenon and thromboangiitis obliterans. The vasoconstrictive mechanism will exacerbate these conditions, leading to immediate tissue death.
3. 3Coronary Artery Disease: Any history of myocardial infarction or angina contraindicates use due to the risk of coronary vasospasm.
4. 4Severe Hepatic or Renal Impairment: The body's inability to metabolize or excrete the alkaloids leads to rapid toxicity.
5. 5Sepsis: In systemic infections, the blood vessels are already compromised, and ergot-induced vasoconstriction can lead to catastrophic organ failure.
6. 6Hypersensitivity: Known allergy to ergot or any fungal proteins.

• Uncontrolled Hypertension: Requires careful stabilization before any exposure.
• Peptic Ulcer Disease: Ergot alkaloids can worsen gastric irritation and increase the risk of GI bleeding.
• Psychosis: Due to the potential for hallucinations and CNS stimulation, patients with a history of schizophrenia or bipolar disorder should be monitored closely.

Patients who are allergic to other fungi (such as Alternaria or Aspergillus) may show cross-reactivity to Claviceps Purpurea Sclerotium. Additionally, those sensitive to one ergot derivative (like dihydroergotamine) are likely sensitive to all products derived from the sclerotium.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing or administering Claviceps Purpurea Sclerotium.

FDA Pregnancy Category X (Equivalent): Claviceps Purpurea Sclerotium is strictly contraindicated during pregnancy. The alkaloids within the sclerotium possess powerful oxytocic properties, meaning they stimulate the muscles of the uterus to contract. Historically used to induce labor, this is now considered extremely dangerous as it can cause uterine rupture and fetal death. Furthermore, the vasoconstrictive effects significantly reduce uterine blood flow, leading to chronic fetal hypoxia and growth retardation. If pregnancy occurs while using ergot derivatives, the medication must be stopped immediately.

Ergot alkaloids are known to pass into breast milk in significant quantities. They can cause symptoms of ergotism in the nursing infant, including vomiting, diarrhea, weak pulse, and unstable blood pressure. Additionally, ergot derivatives are known to inhibit prolactin secretion, which can significantly suppress or completely stop the mother's milk production. Breastfeeding is not recommended while using this substance.

Safety and effectiveness in children have not been established. The use of Claviceps Purpurea Sclerotium in pediatric patients is generally limited to specialized allergy testing. Children are more susceptible to the toxic effects of ergotism, and there is a theoretical risk that the vasoconstrictive properties could interfere with normal vascular development.

Elderly patients (over 65) are at a much higher risk for adverse events. Age-related declines in liver and kidney function mean that ergot alkaloids stay in the system longer. Furthermore, the high prevalence of undiagnosed peripheral vascular disease in the elderly makes the risk of gangrene significantly higher. Clinicians are advised to use the lowest possible concentration for diagnostic testing in this population.

In patients with a GFR below 60 mL/min, the clearance of ergot metabolites is significantly delayed. In severe renal impairment (GFR < 30 mL/min), the use of Claviceps Purpurea Sclerotium is contraindicated. Accumulation of the drug can lead to chronic ergotism, characterized by persistent numbness and cognitive decline.

Patients with Child-Pugh Class B or C hepatic impairment should not be exposed to this substance. Since the CYP3A4 pathway in the liver is the primary means of detoxification, liver failure leads to a rapid and dangerous rise in systemic alkaloid levels.

> Important: Special populations require individualized medical assessment and often require alternative diagnostic or therapeutic options.

Claviceps Purpurea Sclerotium acts as a complex biological ligand for several G-protein coupled receptors. Its primary action is as a partial agonist at alpha-adrenergic receptors (specifically alpha-1), which results in the contraction of vascular smooth muscle. It also acts on 5-HT1B/1D serotonin receptors located on intracranial blood vessels and sensory nerves of the trigeminal system. By stimulating these receptors, it causes vasoconstriction and inhibits the release of pro-inflammatory neuropeptides. The 'Nitrogen Binding' classification refers to its role in ammonium ion processing, which is a secondary metabolic pathway in fungal-derived nitrogenous compounds.

The pharmacodynamic response to Claviceps Purpurea Sclerotium is characterized by a rapid onset of vasoconstriction. The duration of effect is often much longer than the plasma half-life would suggest (up to 24 hours) because the alkaloids bind nearly irreversibly to alpha-receptors in the blood vessel walls. There is a steep dose-response relationship, meaning small increases in dose can lead to massive increases in physiological effect, including dangerous spikes in blood pressure.

| Parameter | Value |

|---|---|

| Bioavailability | < 5% (Oral) |

| Protein Binding | 90% - 95% |

| Half-life | 2 - 3 hours (Alkaloids) |

| Tmax | 0.5 - 2 hours |

| Metabolism | Hepatic (Primary CYP3A4) |

| Excretion | Biliary/Fecal (90%), Renal (10%) |

• Molecular Formula: Complex mixture (Major component Ergotamine: C33H35N5O5)
• Molecular Weight: Variable (Ergotamine: 581.66 g/mol)
• Solubility: Sparingly soluble in water; soluble in organic solvents and acidic solutions.
• Structure: The active components are tetracyclic ergoline derivatives, consisting of an indole ring system.

Claviceps Purpurea Sclerotium is classified as a Non-Standardized Fungal Allergenic Extract and a Nitrogen Binding Agent. It is the biological parent of the Ergot Alkaloid class. Related medications include ergotamine tartrate, dihydroergotamine, and methylergonovine.